共 32 条
[1]
Aithal GP(1999)Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet. 27 717-719
[2]
Day CP(2001)Pharmacogenetics of warfarin elimination and its clinical implications Clin Pharmacokinet. 40 587-603
[3]
Kersteven PJL(1999)Racial background is a determinant of average warfarin dose required to maintain INR between 2.0 and 3.0 Br J Haematol. 107 207-209
[4]
Daly AK(2003)Racial background is a determinant factor in the maintenance dosage of warfarin Int J Haematol. 78 84-86
[5]
Takayashi H(1996)The role of the CYP2C9-Leu Pharmacogenetics. 6 341-349
[6]
Hirotoshi E(1996) allelic variant in the tolbutamide polymorphism Pharmacogenetics. 5 429-439
[7]
Blann A(2003)Genetic analysis of the human cytochrome P450 CYP2C9 locus Clin Pharmacol Ther. 73 253-263
[8]
Hewitt J(1995)Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients Pharmacogenetics. 5 37-42
[9]
Siddiqui F(2001)Detection of CYP2C9 polymorphisms based on the polymerase chain reaction in Chinese. Blood. 98 2584-2587
[10]
Bareford D(undefined)Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients undefined undefined undefined-undefined